Syros to Participate in Upcoming Investor Conferences
Date:
Presentation Time:
Location: New York
TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Date:
Presentation Time:
Location: Virtual
To access the webcasts and subsequent archived recording of each event, please visit the Investors & Media section of the Syros website at www.syros.com. An archived replay of each webcast will be available for approximately 30 days following each presentation.
About
Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARα agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240507063235/en/
Syros Contact
Director of
1-857-327-7321
khunady@syros.com
Investor Contact
Stern Investor Relations, Inc.
212-362-1200
amanda.isacoff@sternir.com
Source: